167 related articles for article (PubMed ID: 30226069)
1. Results of long term testosterone replacement therapy in men with abdominal obesity, erectile dysfunction and testosterone deficiency.
Fillo J; Breza J; Ondrusova M; Luha J; Ondrus D; Dubravicky J; Breza J; Labas P; Levcikova M
Bratisl Lek Listy; 2018; 119(9):577-580. PubMed ID: 30226069
[TBL] [Abstract][Full Text] [Related]
2. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
3. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
4. The effect of long term testosterone replacement therapy on bone mineral density.
Fillo J; Levcikova M; Luha J; Ondrus D
Bratisl Lek Listy; 2019; 120(4):291-294. PubMed ID: 31023052
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy (TRT) and its effect on bone marrow. How serious is it and is there a true polyglobulia?
Levcikova M; Breza J; Luha J; Dubravicky J; Kovacova E; Fillo J
Bratisl Lek Listy; 2017; 118(11):654-657. PubMed ID: 29216720
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
7. [65-month testosterone replacement therapy for androgen deficiency-induced ED: a case report and review of the literature].
Jiang T; Zheng L; Sun DC; Li QL; Zhang ZW; Wang FP; Wang QF; Jiang H
Zhonghua Nan Ke Xue; 2014 Feb; 20(2):152-5. PubMed ID: 24520668
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
[TBL] [Abstract][Full Text] [Related]
9. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.
Balbontin FG; Moreno SA; Bley E; Chacon R; Silva A; Morgentaler A
BJU Int; 2014 Jul; 114(1):125-30. PubMed ID: 25101359
[TBL] [Abstract][Full Text] [Related]
10. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
12. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy.
Salman M; Yassin DJ; Shoukfeh H; Nettleship JE; Yassin A
Aging Male; 2017 Mar; 20(1):45-48. PubMed ID: 28084147
[TBL] [Abstract][Full Text] [Related]
13. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency.
Boyanov MA; Boneva Z; Christov VG
Aging Male; 2003 Mar; 6(1):1-7. PubMed ID: 12809074
[TBL] [Abstract][Full Text] [Related]
14. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome.
McLaren D; Siemens DR; Izard J; Black A; Morales A
BJU Int; 2008 Nov; 102(9):1142-6. PubMed ID: 18540933
[TBL] [Abstract][Full Text] [Related]
15. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
Morgunov LIu; Vertkin AL; Pushkar' DIu
Urologiia; 2007; (5):49-51. PubMed ID: 18254226
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
17. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
[TBL] [Abstract][Full Text] [Related]
18. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Reyes-Vallejo L; Lazarou S; Morgentaler A
J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
[TBL] [Abstract][Full Text] [Related]
19. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
Yassin AA; Nettleship JE; Salman M; Almehmadi Y
Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
Saad F; Yassin A; Doros G; Haider A
Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
